Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Weight loss jabs may offer a protective effect against dementia and stroke, according to a new study. People with type 2 ...

Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment <li /> Combination of oral PL7737 ...

Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment Combination of oral PL7737 and tirzepatide resulted in additive ...

Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

The game-changing weight loss jabs have ushered in a new era in the war on obesity ... that tirzepatide—the ingredient behind Mounjaro—may 'significantly' slow the growth of breast cancer tumours.

Researchers followed 60,000 adults aged 40 and older—who took various types of antidiabetic medication—for seven years ...

Weight loss jabs may offer a protective effect against dementia and stroke, according to a new study. People with type 2 ...